Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 17, 2026
Subject: Announcement of a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorization for FREHEMGO® (denecimig).
Key Financial Metrics
This filing is a regulatory and operational update regarding a specific drug approval. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Operational Updates
- Regulatory Milestone: The CHMP has recommended approval for FREHEMGO® (denecimig) for the treatment of haemophilia A (congenital FVIII deficiency) in adults and children, with or without inhibitors.
- Product Differentiation: FREHEMGO® is the first factor VIIIa mimetic to offer flexible prophylaxis dosing (once-monthly, once-every-two-weeks, and once-weekly) in a single-use pre-filled pen.
- Clinical Evidence: The recommendation is based on the FRONTIER trial programme. Key findings include:
- Significant reduction in annualised bleeding rates compared to prior treatments in the FRONTIER 2 trial.
- Consistent efficacy in children under 12 (FRONTIER 3).
- Low mean annualised bleeding rates (generally below 1) across the phase 3 population.
- No new safety signals identified when switching from emicizumab to denecimig (FRONTIER 5).
- US Status: A Biologics License Application (BLA) was submitted to the US FDA in September 2025.
Guidance, Outlook, and Management Commentary
- Launch Timeline: Novo Nordisk expects to launch FREHEMGO® in the first European countries in Q4 2026, with a broader rollout across the EU starting early 2027.
- Management Commentary: CEO Mike Doustdar stated that the approval builds on over 40 years of commitment to haemophilia. He highlighted the combination of strong bleed protection, flexible dosing, and the pre-filled pen as a differentiated option to reduce treatment burden.
- Risks and Contingencies: The filing notes that the product is currently pending final marketing approval from the EMA and other authorities. No specific financial risks or contingencies were detailed in this announcement.
Key Facts for Investor Verification
- Confirm the final EMA marketing authorization decision following the CHMP positive opinion.
- Monitor the actual launch dates in Q4 2026 and early 2027 against the company's guidance.
- Track the status of the US FDA review following the September 2025 BLA submission.
- Verify the commercial uptake and market share of FREHEMGO® relative to existing emicizumab treatments.
- Review upcoming quarterly financial reports for the impact of FREHEMGO® on revenue and R&D expenses.